Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
Vion Pharmaceuticals Reports 2009 Second Quarter And Six-Month Results
Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin(TM)
Vion Pharmaceuticals Presents Data on Onrigin(TM) Elderly AML Trials at the ASCO(R) Annual Meeting
Vion Pharmaceuticals to Present Data on Onrigin(TM)at the ASCO(R) Annual Meeting
Vion Pharmaceuticals Reports 2009 First Quarter Results
Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin(TM)
Vion Pharmaceuticals' New Drug Application for Onrigin(TM)Accepted For Review by the FDA
Vion Reports 2008 Full-Year and Fourth-Quarter Results
Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)
Vion Pharmaceuticals Presents Additional Survival Data on Onrigin(TM) (Laromustine) Injection at ASH Annual Meeting
Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting
Vion Pharmaceuticals Adds Tanya Lewis to Senior Management Team
Vion Updates Conference Call Information
Vion Reports 2008 Third Quarter and Nine-Month Results
Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
Vion Pharmaceuticals is Delisted from Nasdaq Stock Market
Vion Reports 2008 Second Quarter and Six-Month Results
Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
BeaconEquity.com Issues TraderNotes on Biotechnology Stocks: TPIM, RXII, VION, CUR, AMGN, GILD, BIIB, GENR
Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine - Jun 2 2008 2:04AM
Vion Pharmaceuticals to Appeal Nasdaq Delisting - Jun 2 2008 2:04AM
Vion Pharmaceuticals to Host Conference Call to Discuss 2008 First Quarter Financial Results - Jun 2 2008 2:04AM
Vion Reports 2008 First Quarter Results - Jun 2 2008 2:04AM
Vion Pharmaceuticals Files Plan With Nasdaq
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
